Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(43%)
Results Posted
50%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
5
71%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Recruiting3
Completed2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 25 (71.4%)

Trials by Status

unknown114%
recruiting343%
completed229%
terminated114%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_1

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

NCT04144023
recruitingphase_2

Quadruple Immunotherapy for Neuroblastoma

NCT05754684
terminatedphase_2

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

NCT04856176
recruitingphase_2

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

NCT05817214
completedphase_1

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

NCT03306589
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04144023Phase 1

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Recruiting
NCT05754684Phase 2

Quadruple Immunotherapy for Neuroblastoma

Recruiting
NCT04856176Phase 2

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Terminated
NCT05817214Phase 2

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Recruiting
NCT03306589Phase 1

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

Completed
NCT02663440Phase 2

Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme

Unknown
NCT00004141Phase 2

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7